Answers are grounded in this paper and cite their sources.
The TROPiCS-02 study (NCT03901339) demonstrated that sacituzumab govitecan (SG) has superior clinical outcomes over treatment of physician's choice (TPC) chemotherapy in patients with hormone receptor-positive, human epidermal growth factor 2 receptor-negative (HR+/HER2-) metastatic breast cancer (mBC). Here, we present health-related quality of life (HRQoL) patient-reported outcome (PRO) findings from this study.
No takes yet. Share an insight, caveat, or question.
Rugo et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: